SCHEMBL2457017

SCHEMBL2457017

CC(C)(C)C1=C2C=NC=C[N+]2(N)C(c2cccc(OCc3ccccc3)c2)=N1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.39
NR1H2 P55055 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
PRKDC P78527 1/20 0.37
IGF1R P08069 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
BRD4 O60885 1/20 0.36
BACE1 P56817 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
XBP1 P17861 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
DHODH Q02127 1/20 0.36
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2458332 0.90 NR1H2 (0.39) MAOBNR1H2PIK3CDPIK3CAPIK3CB
SCHEMBL2460381 0.87 MAOB (0.38) MAOBNR1H2MRGPRX4CYP4F2CYP4A11
SCHEMBL2460398 0.86 MAOB (0.41) MAOBNR1H2PIK3CDPIK3CAPIK3CB
SCHEMBL3537072 0.85 MAOB (0.40) MAOBNR1H2PIK3CDPIK3CAPIK3CB
SCHEMBL3538398 0.85 MAOB (0.38) MAOBNR1H2PIK3CDPIK3CAPIK3CB
SCHEMBL3535621 0.85 MAOB (0.38) MAOBNR1H2PIK3CDPIK3CAPIK3CB
SCHEMBL2457734 0.84 NR1H2 (0.41) MAOBNR1H2PIK3CDPIK3CAPIK3CB
SCHEMBL3537676 0.82 MRGPRX4 (0.42) MAOBMRGPRX4DHODH
SCHEMBL2460148 0.82 CFD (0.42) MAOBNR1H2PIK3CDPIK3CAPIK3CB
SCHEMBL2462894 0.81 ALOX5 (0.41) MAOBNR1H2PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 MAOB 1546/4885NR1H2 2603/4885PIK3CD 636/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 MAOB 1546/4885NR1H2 2603/4885PIK3CD 636/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 MAOB 1546/4885NR1H2 2603/4885PIK3CD 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.